---
title: "Evolus, Inc. (EOLS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EOLS.US.md"
symbol: "EOLS.US"
name: "Evolus, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T18:26:46.112Z"
locales:
  - [en](https://longbridge.com/en/quote/EOLS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EOLS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EOLS.US.md)
---

# Evolus, Inc. (EOLS.US)

## Company Overview

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.evolus.com](https://www.evolus.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 78 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.56% |  |
| Net Profit YoY | 22.74% |  |
| P/B Ratio | -14.71 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 423446048.93 |  |
| Revenue | 301791000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 245.43% | A |
| Profit Margin | -14.39% | D |
| Gross Margin | 66.86% | A |
| Revenue YoY | 9.56% | B |
| Net Profit YoY | 22.74% | B |
| Total Assets YoY | 3.41% | C |
| Net Assets YoY | -335.81% | E |
| Cash Flow Margin | 84.25% | C |
| OCF YoY | 9.56% | B |
| Turnover | 1.39 | A |
| Gearing Ratio | 113.04% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Evolus, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.56%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "22.74%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-14.71",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "423446048.93",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "301791000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "245.43%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-14.39%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "66.86%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "9.56%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "22.74%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.41%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-335.81%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "84.25%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "9.56%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "1.39",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "113.04%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.75 | 187/189 | - | - | - |
| PB | -14.71 | 224/189 | - | - | - |
| PS (TTM) | 1.40 | 40/189 | 2.13 | 1.51 | 1.10 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 71% |
| Overweight | 1 | 14% |
| Hold | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.55 |
| Highest Target | 20.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/EOLS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/EOLS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/EOLS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/EOLS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**